Neonatal cardiac transplantation. Intermediate-term results and incidence of rejection. Loma Linda University Pediatric Heart Transplant Group

Arch Surg. 1992 Sep;127(9):1072-5; discussion 1075-6. doi: 10.1001/archsurg.1992.01420090080011.

Abstract

Early age at cardiac transplantation may favor successful engrafting with minimal chronic immunosuppression. Fifty-two newborns underwent orthotopic heart transplantation; 47 (90%) survived the operation, and 44 (85%) were late survivors. Actuarial survival was 92% at 1 month, 86% at 1 year, and 84% at 5 years. Forty-four infants who survived 12 weeks and the corresponding 100 rejection episodes were analyzed. Mean follow-up was 2.2 years. The mean number of rejections per year of follow-up was 1.2. No episodes of rejection were identified in six patients. Seven patients had a late rejection episode more than 1 year after transplantation, and only one had a late rejection episode after 2 years. Neonatal cardiac transplantation is effective and durable therapy for uncorrectable heart disease. Intermediate-term results are excellent. Severe rejection is uncommon, and few episodes occur after 1 year of follow-up.

MeSH terms

  • Azathioprine / administration & dosage
  • Azathioprine / therapeutic use
  • Cause of Death
  • Confidence Intervals
  • Cyclosporine / administration & dosage
  • Cyclosporine / therapeutic use
  • Female
  • Follow-Up Studies
  • Graft Rejection*
  • Heart Defects, Congenital / surgery
  • Heart Transplantation* / methods
  • Humans
  • Immunosuppression Therapy
  • Incidence
  • Infant, Newborn*
  • Male
  • Survival Rate
  • Time Factors

Substances

  • Cyclosporine
  • Azathioprine